Trial · NCT01706458
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Immune Response Following Treatment | Sipuleucel-T | 6 | Participants | ||
| Number of Participants With Immune Response Following Treatment | Sipuleucel-T With DNA Vaccine | 5 | Participants | ||
| Progression-free Survival | Sipuleucel-T | 0 | Participants | ||
| Progression-free Survival | Sipuleucel-T With DNA Vaccine | 0 | Participants | ||
| Time to Radiographic Disease Progression | Sipuleucel-T | 161 | Full Range 85 to 259 | days | |
| Time to Radiographic Disease Progression | Sipuleucel-T With DNA Vaccine | 164 | Full Range 85 to 343 | days | |
| Measure Prostate-specific Antigen (PSA) Doubling Time | Sipuleucel-T | 2.5 | 95% Confidence Interval 1.1 to 8.8 | months | |
| Measure Prostate-specific Antigen (PSA) Doubling Time | Sipuleucel-T With DNA Vaccine | 2.6 | 95% Confidence Interval 1.7 to 3.6 | months | |
| Overall Survival: Median Time to Death From Any Cause | Sipuleucel-T | 32.3 | 95% Confidence Interval 7.7 to 66.7 | months | |
| Overall Survival: Median Time to Death From Any Cause | Sipuleucel-T With DNA Vaccine | 29.6 | 95% Confidence Interval 14.6 to 46.0 | months | |
| PAP-specific Antibody and T-cell Immune Responses Following Treatment With Sipuleucel-T and DNA Vaccine | Sipuleucel-T | Interferon Gamma Response | 3 | Participants | |
| PAP-specific Antibody and T-cell Immune Responses Following Treatment With Sipuleucel-T and DNA Vaccine | Sipuleucel-T With DNA Vaccine | Interferon Gamma Response | 2 | Participants | |
| PAP-specific Antibody and T-cell Immune Responses Following Treatment With Sipuleucel-T and DNA Vaccine | Sipuleucel-T | Granzyme B | 4 | Participants | |
| PAP-specific Antibody and T-cell Immune Responses Following Treatment With Sipuleucel-T and DNA Vaccine | Sipuleucel-T With DNA Vaccine | Granzyme B | 4 | Participants | |
| PAP-specific Antibody and T-cell Immune Responses Following Treatment With Sipuleucel-T and DNA Vaccine | Sipuleucel-T | Antibody Response | 3 | Participants | |
| PAP-specific Antibody and T-cell Immune Responses Following Treatment With Sipuleucel-T and DNA Vaccine | Sipuleucel-T With DNA Vaccine | Antibody Response | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01706458/results